Conference Coverage

Economic burden of migraine increases with the number of treatment failures


 

From AAN 2020

Among patients with migraine, increase in the number of treatment failures is associated with increase in economic burden, researchers wrote. Utilization of health care resources and associated costs are greater among patients with three or more treatment failures, compared with patients with fewer treatment failures. This research was presented online as part of the 2020 American Academy of Neurology Science Highlights.

Dr. Lawrence C. Newman, director of the division of headache at NYU Langone Health in New York

Dr. Lawrence C. Newman

Migraine entails a significant economic burden, including direct costs (e.g., medical costs) and indirect costs (e.g., lost productivity). Information about the burden associated with failed preventive treatments among migraineurs is limited, however. Lawrence C. Newman, MD, director of the division of headache at NYU Langone Health in New York, and colleagues conducted a study to characterize health care resource utilization (HCRU) and its associated costs among migraineurs, stratified by the number of preventive treatment failures.

About one quarter of patients had two treatment failures

Using data from the IBM MarketScan Commercial and Medicare Supplemental database, Dr. Newman and colleagues identified patients who received a new diagnosis of migraine between Jan. 1, 2011, and June 30, 2015. Next, they identified the number of treatment failures during the 2 years following the initial migraine diagnosis. They assessed HCRU and associated costs during the 12 months following an index event. The index was the date of initiation of the second preventive treatment for patients with one treatment failure, the date of initiation of the third treatment for patients with two treatment failures, and the date of initiation of the fourth treatment for patients with three or more treatment failures.

Dr. Newman’s group identified 44,181 patients with incident migraine who had failed preventive treatments. Of this population, 27,112 patients (61.4%) had one treatment failure, 10,583 (24%) had two treatment failures, and 6,486 (14.7%) had three or more treatment failures.

The total medical cost per patient, including emergency room (ER), inpatient (IP), and outpatient (OP) care, increased with increasing number of treatment failures ($10,329 for one, $13,774 for two, and $35,392 for three or more). When the investigators added prescription drug costs, the total health care costs also increased with number of treatment failures ($13,946 for one, $18,685 for two, and $41,864 for three or more).

Similarly, the per-patient annual health care provider visits increased with increasing numbers of treatment failures. The number of ER visits per year was 0.54, 0.69, and 1.02 for patients with one, two, and three or more treatment failures, respectively. The annual number of IP visits was 0.46, 0.59, and 0.97, for patients with one, two, and three or more treatment failures, respectively. OP visits showed a similar trend. The annual number of office visits was 9.47 for patients with one, 11.24 for patients with two, and 14.26 for patients with three or more treatment failures. The annual number of other visits was 13.15 for patients with one, 15.73 for patients with two, and 19.96 for patients with three or more treatment failures.

Pages

Recommended Reading

FDA approves first IV migraine prevention drug
MDedge Family Medicine
FDA OKs first orally disintegrating agent for rapid migraine relief
MDedge Family Medicine
Expert says progress in gut-brain research requires an open mind
MDedge Family Medicine
Researchers develop score to predict risk of stroke among migraineurs with aura
MDedge Family Medicine
Do urgent care centers use optimal medications for acute migraine?
MDedge Family Medicine
How can neurologists diagnose and treat menstrual migraine?
MDedge Family Medicine
When is preventive treatment of migraine appropriate?
MDedge Family Medicine
Pandemic necessitates new strategies to treat migraine
MDedge Family Medicine
How do neurologists choose an acute treatment for migraine?
MDedge Family Medicine
CGRP inhibitors receive reassuring real-world safety report
MDedge Family Medicine